In this issue:
Durable efficacy of nemolizumab in paediatric AD
Switching to less frequent tralokinumab efficacious
Longer-term lebrikizumab efficacious after suboptimal response to induction
Effectiveness of long-term upadacitinib in real-world settings
Infants with AD at higher risk for other atopic diseases
Interim results from the PEDISTAD realworld registry
JAK inhibitors are safe and effective in older patients
Increased risk of conjunctivitis and keratitis with dupilumab
Upadacitinib retreatment after withdrawal is effective
Smoking does not impact the safety profile of upadacitinib
Please login below to download this issue (PDF)